C

Coya Therapeutics Inc
NASDAQ:COYA

Watchlist Manager
Coya Therapeutics Inc
NASDAQ:COYA
Watchlist
Price: 5.97 USD 3.47% Market Closed
Market Cap: 99.8m USD

Coya Therapeutics Inc
Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Coya Therapeutics Inc
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
C
Coya Therapeutics Inc
NASDAQ:COYA
Common Stock
$1.4k
CAGR 3-Years
-95%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Common Stock
$18m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Common Stock
$33.4B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Common Stock
$2.6m
CAGR 3-Years
-5%
CAGR 5-Years
-3%
CAGR 10-Years
3%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Common Stock
$101.8k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Coya Therapeutics Inc
Glance View

Market Cap
90.9m USD
Industry
Biotechnology

Coya Therapeutics, Inc. is a clinical-stage biotechnology company engaged in developing approaches utilizing Treg modifying therapeutics to target systemic and neuro inflammation. The company is headquartered in Houston, Texas. The company went IPO on 2022-12-29. The firm is focused on developing new therapies to enhance the function of regulatory T cells (Tregs). The company is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases. The company has a diversified product candidate pipeline that includes both ex vivo (outside the body) and in vivo (inside the body) therapeutic approaches intended to restore the suppressive and immunomodulatory functions of Tregs. Its 300 Series product candidates include COYA 301 and COYA 302, its 200 Series product candidates include COYA 201 and COYA 206, and its 100 Series product candidate is COYA 101. Its COYA 301 is a biologic for subcutaneous administration. Its COYA 302 is a combination of two molecules for subcutaneous and/or intravenous administration. Its COYA 201 product candidate utilizes its Treg-derived exosome therapeutic modality. Its COYA 101 is its autologous regulatory T-cell product candidate.

COYA Intrinsic Value
2.27 USD
Overvaluation 62%
Intrinsic Value
Price
C

See Also

What is Coya Therapeutics Inc's Common Stock?
Common Stock
1.4k USD

Based on the financial report for Dec 31, 2023, Coya Therapeutics Inc's Common Stock amounts to 1.4k USD.

What is Coya Therapeutics Inc's Common Stock growth rate?
Common Stock CAGR 3Y
-95%

Over the last year, the Common Stock growth was -100%. The average annual Common Stock growth rates for Coya Therapeutics Inc have been -95% over the past three years .

Back to Top